04:25 PM EDT, 05/13/2024 (MT Newswires) -- Harrow Health (HROW) reported a Q1 core net loss of $0.28 per diluted shares, widening from $0.03 loss a year earlier.

Analysts polled by Capital IQ expected $0.25 loss.

Revenue for the quarter ended March 31 was $34.6 million, up from $26.1 million a year earlier. Analysts surveyed by Capital IQ expected $36.3 million.

CEO Mark Baum said he remains optimistic for 2024.

"Given the strength we see with both IHEEZO and VEVYE, the upcoming re-introduction of TRIESENCE to the ophthalmic market, and the significant momentum that we have built so far in 2024, we are well positioned to meet our 2024 revenue guidance of more than $180 million," Baum said.

The company share were up over 10% in recent after-hours activity.

Price: 13.30, Change: +1.23, Percent Change: +10.19